The global seasonal influenza vaccines therapeutics industry has shown robust growth in recent years, marking a significant valuation of around US$ 7.2 Billion by the end of 2021. This market, driven by the increasing prevalence of seasonal flu and the continuous evolution of the vaccine landscape, is forecasted to soar at a remarkable Compound Annual …